Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

SavannahGuzman Jun. 16 at 2:12 PM

$GNLX

0 · Reply

LeroyGrant Jun. 16 at 1:13 PM

$GNLX

0 · Reply

Kupper Jun. 13 at 9:07 PM

$GNLX Irritating to see the attack of the shithead shorts as soon as this runs up.

0 · Reply

RunnerSignals Jun. 13 at 8:25 PM

comeback kings $GNLX soared $ELVN came alive $EU fueled up $GEVO sparked interest and $CLNE cleaned up with a tidy close

0 · Reply

Shakescene1 Jun. 13 at 7:00 PM

$GNLX popin today - interesting - perhaps more frontline datasets on olvi vec? I don’t know

0 · Reply

Johnm_ Jun. 10 at 12:00 PM

$GNLX Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know https://finance.yahoo.com/news/genelux-corporation-gnlx-upgraded-buy-160007749.html

0 · Reply

Kupper Jun. 4 at 3:21 PM

$GNLX time to buy more. Thanks idiots for bringing it down to my buy range again.

2 · Reply

Shakescene1 Jun. 3 at 8:03 PM

$GNLX gonna rip in ‘26

0 · Reply

ASseenONtv Jun. 2 at 3:52 PM

$GNLX Nothing but crickets

1 · Reply

Kupper May. 29 at 11:41 PM

$GNLX every time this drops below $2.50 I buy more. It will be worth at least 10X that once they get approvals.

0 · Reply

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Mar 28, 2025, 4:10 PM EDT - 2 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 8:31 AM EDT - 2 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 4 months ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 6 months ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 7 months ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 31, 2024, 10:59 AM EDT - 8 months ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 22, 2024, 4:01 PM EDT - 8 months ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 8 months ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 10 months ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 10 months ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 11 months ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 1 year ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 1 year ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 30, 2023, 1:56 PM EDT - 1 year ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 26, 2023, 10:50 PM EDT - 2 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 2 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 2 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 1:49 PM EDT - 2 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 9:08 AM EDT - 2 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

SavannahGuzman Jun. 16 at 2:12 PM

$GNLX

0 · Reply

LeroyGrant Jun. 16 at 1:13 PM

$GNLX

0 · Reply

Kupper Jun. 13 at 9:07 PM

$GNLX Irritating to see the attack of the shithead shorts as soon as this runs up.

0 · Reply

RunnerSignals Jun. 13 at 8:25 PM

comeback kings $GNLX soared $ELVN came alive $EU fueled up $GEVO sparked interest and $CLNE cleaned up with a tidy close

0 · Reply

Shakescene1 Jun. 13 at 7:00 PM

$GNLX popin today - interesting - perhaps more frontline datasets on olvi vec? I don’t know

0 · Reply

Johnm_ Jun. 10 at 12:00 PM

$GNLX Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know https://finance.yahoo.com/news/genelux-corporation-gnlx-upgraded-buy-160007749.html

0 · Reply

Kupper Jun. 4 at 3:21 PM

$GNLX time to buy more. Thanks idiots for bringing it down to my buy range again.

2 · Reply

Shakescene1 Jun. 3 at 8:03 PM

$GNLX gonna rip in ‘26

0 · Reply

ASseenONtv Jun. 2 at 3:52 PM

$GNLX Nothing but crickets

1 · Reply

Kupper May. 29 at 11:41 PM

$GNLX every time this drops below $2.50 I buy more. It will be worth at least 10X that once they get approvals.

0 · Reply

Kupper May. 28 at 6:50 PM

$GNLX More good news brought price down again.

1 · Reply

cllebye May. 26 at 3:40 PM

$GNLX Genelux’s announcement that it intends to file a Biologics License Application (BLA) for Olvi-Vec before the first half of 2026 is a significant development — especially since the BLA marks the final step toward FDA approval and commercialization.

0 · Reply

Johnm_ May. 23 at 3:55 PM

$GNLX Corporate Presentation May 2025 https://investors.genelux.com/static-files/ce819305-54c9-4be7-bef2-2980d8d7b15d

0 · Reply

Johnm_ May. 22 at 2:06 PM

$GNLX

0 · Reply

Johnm_ May. 22 at 12:47 PM

$ALLR On Breakout watch $GNLX $PHRRF $XBI $PRPH

0 · Reply

Kupper May. 21 at 6:52 PM

$GNLX positive earnings report and increase in cash, and of course stock price goes down 10%.

0 · Reply

Johnm_ May. 21 at 6:38 PM

$GNLX

0 · Reply

Johnm_ May. 21 at 12:06 PM

$ALLR - Trending $XBI $GNLX $PHRRF $PRPH -

0 · Reply

Johnm_ May. 14 at 4:05 PM

$GNLX Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates! Want to read the full release? Visit https://loom.ly/Hi9Y034 #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech

0 · Reply

AmaraNic May. 12 at 7:33 PM

$GNLX its a Green Day wtf

1 · Reply

Armonica423 May. 10 at 11:57 PM

$GNLX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

splendor May. 8 at 6:34 PM

$GNLX

0 · Reply

Market Cap	115.47M
Revenue (ttm)	10,000.00
Net Income (ttm)	-29.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-298,700.02%
Debt to Equity Ratio	0.00

Volume	579,600
Avg Vol	167,582
Day's Range	N/A - N/A
Shares Out	37.74M
Stochastic %K	82%
Beta	-0.49
Analysts	Strong Sell
Price Target	$17.60